The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer
BJU International · 2024-04 · 133 (S4) · 27-36
DOI: 10.1111/bju.16214 ↗Kurz gefasst
Studienprotokoll in der Zeitschrift BJU International, online erschienen am 13.11.2023. Verfasst von Dominic Bagguley und 9 weiteren Autor:innen. Beteiligte Einrichtung: EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Richmond, Victoria, Australia. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Epworth Medical Foundation.
Abstract (Originalsprache)
Objectives Primary objectives: To determine the additive value of prostate‐specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in the risk stratification of men with newly diagnosed prostate cancer (PCa) who would have otherwise been deemed suitable for active surveillance (AS). Specifically, we aim to determine if PSMA PET/CT can detect a cohort of men on AS that are in fact high risk and likely to experience unfavourable outcomes should they remain on their current treatment pathway. Secondary objectives: to determine the additive value of PSMA PET/CT to repeat multiparametric magnetic resonance imaging (mpMRI) of the prostate and explore whether a confirmatory biopsy may be avoided in men with a negative PSMA PET/CT and a negative repeat mpMRI of the prostate (Prostate Imaging‐Reporting and Data System score of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- EJ Whitten Foundation Prostate Cancer Research Centre at Epworth, Richmond, Victoria, Australia.
- Department of Surgery, University of Melbourne, Parkville, Victoria, Australia.
- Urology Unit, Royal Melbourne Hospital, Parkville, Victoria, Australia.
- Research Development and Governance Unit, Epworth HealthCare, Richmond, Victoria, Australia.
- Health Sciences and Biostatistics, Swinburne University of Technology, Hawthorn, Victoria, Australia.
- Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
ORCID-Profile: Gideon Ptasznik, Sean Ong, Nathan Lawrentschuk
Förderung
- Epworth Medical Foundation
Zitieren
APA
Bagguley, D., Harewood, L., McKenzie, D., Ptasznik, G., Ong, S., Chengodu, T., Woon, D., Sim, K., Sheldon, J., & Lawrentschuk, N. (2024). The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer. BJU International, 133(S4), 27-36. https://doi.org/10.1111/bju.16214
Vancouver
Bagguley D, Harewood L, McKenzie D, Ptasznik G, Ong S, Chengodu T, et al. The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer. BJU International. 2024;133(S4):27-36. doi:10.1111/bju.16214
BibTeX
@article{Bagguley2024,
author = {Bagguley, Dominic and Harewood, Laurence and McKenzie, Dean and Ptasznik, Gideon and Ong, Sean and Chengodu, Thilakavathi and Woon, Dixon and Sim, Kenneth and Sheldon, James and Lawrentschuk, Nathan},
title = {The CONFIRM trial protocol: the utility of prostate‐specific membrane antigen positron emission tomography/computed tomography in active surveillance for prostate cancer},
journal = {BJU International},
year = {2024},
volume = {133},
number = {S4},
pages = {27--36},
doi = {10.1111/bju.16214}
}
EUVIMED